Journal Article

Molnupiravir: Mechanism of action, clinical, and translational science

Rizk, Matthew L., Cheng, Mickie, Strizki, Julie, Kumar, Sushma, Brown, Michelle, De Anda, Carisa, Stone, Julie A., Johnson, Matthew G., Maas, Brian M., Miller, Randy R.

2024

Overview

Molnupiravir is an oral prodrug of the broadly active, antiviral ribonucleoside analog N‐hydroxycytidine (NHC). The primary circulating metabolite NHC is taken up into cells and phosphorylated to NHC‐triphosphate (NHC‐TP). NHC‐TP serves as a competitive substrate for viral RNA‐dependent RNA polymerase (RdRp), which results in an accumulation of errors in the viral genome, rendering virus replication incompetent. Molnupiravir has demonstrated activity against SARS‐CoV‐2 both clinically and preclinically and has a high barrier to development of viral resistance. Little to no molnupiravir is observed in plasma due to rapid hydrolysis to NHC. Maximum concentrations of NHC are reached at 1.5 h following administration in a fasted state. The effective half‐life of NHC is 3.3 h, reflecting minimal accumulation in the plasma following twice‐daily (Q12H) dosing. The terminal half‐life of NHC is 20.6 h. NHC‐TP exhibits a flatter profile with a lower peak‐to‐trough ratio compared with NHC, which supports Q12H dosing. Renal and hepatic pathways are not major routes of elimination, as NHC is primarily cleared by metabolism to uridine and cytidine, which then mix with the endogenous nucleotide pools. In a phase III study of nonhospitalized patients with COVID‐19 (MOVe‐OUT), 5 days of treatment with 800 mg molnupiravir Q12H significantly reduced the incidence of hospitalization or death compared with placebo. Patients treated with molnupiravir also had a greater reduction in SARS‐CoV‐2 viral load and improved clinical outcomes, compared with those receiving placebo. The clinical effectiveness of molnupiravir has been further demonstrated in several real‐world evidence studies. Molnupiravir is currently authorized or approved in more than 25 countries.

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
• Subject: Adenosine / Antiviral drugs / Bioavailability / Clinical trials / Competition / COVID-19 / Cytidine - analogs & derivatives / Cytidine - pharmacology / DNA-directed RNA polymerase / Dosage / Drug dosages / Drug resistance / FDA approval / Genomes / Health care / Hospitalization / Humans / Hydroxylamines / Metabolism / Metabolites / Mini Review / Mini Reviews / Patients / Pharmacokinetics / Placebos / Plasma / Public health / Regulatory approval / Ribonucleosides / RNA polymerase / RNA-directed RNA polymerase / SARS-CoV-2 / Severe acute respiratory syndrome coronavirus 2 / Translational Science, Biomedical / Uridine / Viruses